Lipocine Receives Health Canada Approval for TLANDO Testosterone Therapy

Key Facts

1Health Canada approved Lipocine's TLANDO capsules for testosterone replacement therapy in adult males.

2Verity Pharmaceuticals holds exclusive North American commercial rights and plans a Canadian launch by late 2026.

Health Canada approved Lipocine's TLANDO capsules for testosterone replacement therapy in adult males. PR Newswire reported that Verity Pharmaceuticals holds exclusive North American commercial rights and plans to launch the product in Canada by late 2026.

LPCN closed at $2.1 on October 6, 2026, with the stock reaching a day high of $2.1 and a low of $2.07. This regulatory milestone enables the commercialization of the oral therapy in the Canadian market through the company's licensing partnership.